CJC-1295 with DAC 2mg

Manufacturer: Euro-Pharmacies, Europe

Pharmaceutical name: Drug Affinity Complex: Growth Hormone-Releasing Factor

Pack: 1 vial (2 mg)

CJC-1295 peptide with DAC, also referred to as DAC:GRF, is a synthetic replica of a segment of the naturally occurring growth hormone-releasing hormone (GHRH). The structure of CJC-1295 with DAC is founded on the initial 29 amino acids of endogenous GHRH, as these 29 building blocks are essential for complete biological activity.

 

Neverthe less, this peptide has been further modified by replacing four amino acids to enhance its stability and effectiveness in comparison to the previous version of CJC-1295 without DAC. The substitution of these four amino acids enables the peptide to bind permanently to the albumin protein within the body, reducing the degradation and oxidation of the peptide, thereby enhancing its stability. Additionally, these modified amino acids increase the peptide's binding affinity to the GHRH receptor, boosting its potency. GHRH is vital for the natural secretion of growth hormone and plays a crucial role in achieving optimal growth during development.

 

CJC-1295 functions by promoting growth hormone secretion through binding to GHRH receptors, stimulating the release of the entire family of growth hormone peptides typically secreted by the pituitary gland. These hormones contribute to increased bone density and collagen production, enhance immune function, and promote the development of lean muscle mass.

 

CJC-1295 with DAC can be used in conjunction with growth hormone-releasing peptides to achieve improved results in peptide cycling. CJC-1295 DAC is often used alongside growth hormone replacement peptides such as GHRP-6 or GHRP-2. The combined administration of CJC-1295 DAC with GHRPs accelerates fat loss, aids in weight reduction, and stimulates anabolic effects through growth hormone-induced fat breakdown. Overall, CJC-1295 with DAC promotes protein synthesis and supports the growth of lean muscle tissue. Additionally, the peptide facilitates quicker recovery from injuries, reduces body fat, and enhances muscle mass. The growth-enhancing properties of CJC-1295 DAC also promote cell growth and division, improving skin health, healing, and immune function.

 

This peptide should not be mistaken for CJC-1295 without DAC since their chemical properties differ significantly, impacting dosing requirements. CJC-1295 DAC has an approximate half-life of 8 days after injection. CJC-1295 with DAC should be administered subcutaneously, allowing for a weekly injection at doses of 100 mcg or 200 mcg, thanks to its prolonged half-life. This injection strategy for CJC-1295 DAC results in an extended overall increase in growth hormone levels. A weekly dose of CJC-1295 with DAC can be combined (stacked) with other GHRPs, such as GHRP-6 or GHRP-2.

 

Numerous studies have documented the growth-enhancing effects and safety of GHRH in children with growth hormone deficiencies. Various treatment methods, including intravenous pulses, intranasal administration, subcutaneous injections, and continuous infusion, have shown that the growth-promoting effect of GHRH correlates with the dosage and frequency of treatment. No unexpected adverse effects have been noted after prolonged use, regardless of the administration method. However, some mild side effects may occur, such as fatigue, euphoria (head rush), water retention, and tingling or numbness. Adhering to the recommended dosages will help mitigate the risk of side effects.